Skip to main content
Equibles

Qube Research & Technologies Ltd

Position in MLTX — MoonLake Immunotherapeutics

CIK 1729829 LONDON, X0
Back to MLTX Full portfolio

Position in MLTX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$9,661,831
+$8,861,859 QoQ
Shares Held
496,242
+1056.3% QoQ
Ownership
0.583%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#29
of 172 holders
Holding Since
Dec 2023
4 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in MLTX Over Time

Shares Held

Position Value (USD)

Derivatives in MLTX

reported options exposure · as of Mar 31, 2024
CallValue
$567,599
CallShares
11,300
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Qube Research & Technologies Ltd holds $2,437,858,262 across 168 Biotechnology names. MLTX ranks #47 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ALNY
Alnylam Pharmaceuticals, Inc.
 798,715 $240,437,176
2 INSM
INSMED Inc
 1,682,334 $179,370,451
3 REGN
Regeneron Pharmaceuticals, Inc.
 221,607 $138,180,828
4 ROIV
Roivant Sciences Ltd.
 3,454,496 $122,254,613
5 AXSM
Axsome Therapeutics, Inc.
 426,336 $104,354,262
6 APGE
Apogee Therapeutics, Inc.
 659,678 $87,559,060
7 TVTX
Travere Therapeutics, Inc.
 1,443,230 $81,989,896
8 RPRX
Royalty Pharma plc
 1,412,112 $79,177,119

All Filings in MLTX

Export CSV
5 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $9,661,831 496,242
2026-03-31 $799,972 42,917
2024-03-31 $284,050 5,655
2024-03-31 $567,599 11,300
2023-12-31 $1,142,578 18,920